1
1 of 2
- Long Ridge Medical Center260 Long Ridge RoadStamford, CT 06902
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
Mariya Rozenblit, MD
Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine, Hematology (Internal Medicine)
, and Medical Oncology
Biography
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Internal Medicine ResidentNYU Langone Medical Center (2018)
- MDIcahn School of Medicine at Mount Sinai (2015)
- BAColumbia University, Biology (2009)
Additional Information
Honors & Recognitions
- Susan G. Komen Career Catalyst Award: (2022)
- ASCO Conquer Cancer Foundation Young Investigator Award: (2020)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2022)
- AB of Internal Medicine, Medical Oncology (2022)
- AB of Internal Medicine, Internal Medicine (2018)
Publications
- Lambertini M, Blondeaux E, Agostinetto E, Hamy-Petit A, Kim H, Chiodi C, Bernstein-Molho R, Hilbers F, Pogoda K, Lopez E, Punie K, Bajpai J, Ignatiadis M, Moore H, Phillips K, Toss A, Rousset-Jablonski C, Peccatori F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Garza C, De Marchis L, Mastro L, Puglisi F, Estevez-Diz M, Rodriguez-Wallberg K, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalińska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Azim H, Partridge A. Abstract GS02-13: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study. Cancer Research 2024, 84: gs02-13-gs02-13. DOI: 10.1158/1538-7445.sabcs23-gs02-13.
- Rozenblit M, Kahn A, Gong G, Williams A, Pusztai L. Abstract PO5-18-11: Use of DiviTum®TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer. Cancer Research 2024, 84: po5-18-11-po5-18-11. DOI: 10.1158/1538-7445.sabcs23-po5-18-11.
- Blansky D, Lustberg M, Pusztai L, Rozenblit M. Abstract PO2-06-02: Characteristics and Treatment Patterns of de novo Oligometastatic Stage IV Breast Cancer: A Single-Center Retrospective Cohort Study. Cancer Research 2024, 84: po2-06-02-po2-06-02. DOI: 10.1158/1538-7445.sabcs23-po2-06-02.
- Rozenblit M, Wiesendanger N, Shanahan K, Hodgdon C, Gershkovich P, Golshan M, Moran M, Lustberg M, Pusztai L. Abstract PO5-18-12: Can we cure de novo oligometastatic stage IV HER2+ breast cancer with multimodality therapy? (CHLOE). Cancer Research 2024, 84: po5-18-12-po5-18-12. DOI: 10.1158/1538-7445.sabcs23-po5-18-12.
- Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.
- Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.
- Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Sehgal R, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. Science Advances 2023, 9: eadf4163. PMID: 37467337, PMCID: PMC10355820, DOI: 10.1126/sciadv.adf4163.
- Rozenblit M, Lin H, Can N, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner F, Pusztai L. Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®. Cancer Research 2023, 83: p2-23-14-p2-23-14. DOI: 10.1158/1538-7445.sabcs22-p2-23-14.
- Minteer C, Thrush K, Niimi P, Rozowsky J, Liu J, Frank M, McCabe T, Hofstatter E, Rozenblit M, Pusztai L, Beckman K, Gerstein M, Levine M. Abstract PR009: Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome. Cancer Research 2023, 83: pr009-pr009. DOI: 10.1158/1538-7445.agca22-pr009.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.
- Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.
- Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Institute 2022, 114: 988-995. PMID: 35417011, PMCID: PMC9275765, DOI: 10.1093/jnci/djac068.
- Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer. Annals Of Translational Medicine 2022, 0: 0-0. PMID: 35530962, PMCID: PMC9073796, DOI: 10.21037/atm-22-484.
- Rozenblit M, Hofstatter E, Liu Z, O’Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics 2022, 14: 30. PMID: 35209953, PMCID: PMC8876160, DOI: 10.1186/s13148-022-01249-z.
- Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes. Cancer Research 2022, 82: p3-07-01-p3-07-01. DOI: 10.1158/1538-7445.sabcs21-p3-07-01.
- Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
- Rozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Cancer Research 2021, 81: ps5-08-ps5-08. DOI: 10.1158/1538-7445.sabcs20-ps5-08.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
- Rozenblit M, Pusztai L, Adelson K, Mougalian S. Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy. Cancer Research 2020, 80: p1-19-12-p1-19-12. DOI: 10.1158/1538-7445.sabcs19-p1-19-12.
- Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.
- Rozenblit M, Heguy A, Chiriboga L, Loomis C, Darvishian F, Egeblad M, Shao Y, Adams S. Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod. Journal Of Clinical Oncology 2017, 35: e12541-e12541. DOI: 10.1200/jco.2017.35.15_suppl.e12541.
- McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. Journal Of Oncology 2016, 2016: 4324863. PMID: 27382369, PMCID: PMC4921638, DOI: 10.1155/2016/4324863.
- Suárez-Fariñas M, Ungar B, da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, Xu H, Zheng X, Peng X, Estrada YD, Dillon SR, Krueger JG, Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. Journal Of Allergy And Clinical Immunology 2015, 135: 1218-1227. PMID: 25840722, DOI: 10.1016/j.jaci.2015.03.003.
- Rozenblit M, Guttman‐Yassky E. Contact Dermatitis. 2015, 25-35. DOI: 10.1002/9781118609125.ch3.
- da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Khattri S, Ungar B, Finney R, Xu H, Zheng X, Estrada YD, Peng X, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. Journal Of Allergy And Clinical Immunology 2015, 135: 712-720. PMID: 25583101, DOI: 10.1016/j.jaci.2014.11.017.
- Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. Journal Of Allergy And Clinical Immunology 2015, 135: 153-163. PMID: 25567045, PMCID: PMC4452382, DOI: 10.1016/j.jaci.2014.10.037.
- Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. Journal Of Allergy And Clinical Immunology 2014, 134: 955-957. PMID: 24996261, PMCID: PMC4281263, DOI: 10.1016/j.jaci.2014.05.024.
- Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.
- Dhingra N, Shemer A, da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, Finney R, Czarnowicki T, Zheng X, Xu H, Estrada YD, Cardinale I, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. Journal Of Allergy And Clinical Immunology 2014, 134: 362-372. PMID: 24768652, DOI: 10.1016/j.jaci.2014.03.009.
- Rozenblit M. 2011 Runner-Up Essay Incentives for Medical School Students to Practice Primary Care through the Lens of John Rawls. The AMA Journal Of Ethic 2012, 14: 970-976. PMID: 23351945, DOI: 10.1001/virtualmentor.2012.14.12.conl4-1212.
- Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.
- Wang G, Drake C, Rozenblit M, Zhou P, Alves S, Herrick S, Hayashi S, Warrier S, Iadecola C, Milner T. Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla. Brain Research 2006, 1094: 163-178. PMID: 16696957, DOI: 10.1016/j.brainres.2006.03.089.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/738528793.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/753995509.
Departments and Programs
Locations
1
1 of 2
- Long Ridge Medical Center260 Long Ridge RoadStamford, CT 06902
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
Biography
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Titles
- Assistant Professor of Medicine (Medical Oncology)
Education & Training
- Internal Medicine ResidentNYU Langone Medical Center (2018)
- MDIcahn School of Medicine at Mount Sinai (2015)
- BAColumbia University, Biology (2009)
Additional Information
Honors & Recognitions
- Susan G. Komen Career Catalyst Award: (2022)
- ASCO Conquer Cancer Foundation Young Investigator Award: (2020)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2022)
- AB of Internal Medicine, Medical Oncology (2022)
- AB of Internal Medicine, Internal Medicine (2018)
Publications
- Lambertini M, Blondeaux E, Agostinetto E, Hamy-Petit A, Kim H, Chiodi C, Bernstein-Molho R, Hilbers F, Pogoda K, Lopez E, Punie K, Bajpai J, Ignatiadis M, Moore H, Phillips K, Toss A, Rousset-Jablonski C, Peccatori F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Garza C, De Marchis L, Mastro L, Puglisi F, Estevez-Diz M, Rodriguez-Wallberg K, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalińska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Azim H, Partridge A. Abstract GS02-13: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study. Cancer Research 2024, 84: gs02-13-gs02-13. DOI: 10.1158/1538-7445.sabcs23-gs02-13.
- Rozenblit M, Kahn A, Gong G, Williams A, Pusztai L. Abstract PO5-18-11: Use of DiviTum®TKa as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer. Cancer Research 2024, 84: po5-18-11-po5-18-11. DOI: 10.1158/1538-7445.sabcs23-po5-18-11.
- Blansky D, Lustberg M, Pusztai L, Rozenblit M. Abstract PO2-06-02: Characteristics and Treatment Patterns of de novo Oligometastatic Stage IV Breast Cancer: A Single-Center Retrospective Cohort Study. Cancer Research 2024, 84: po2-06-02-po2-06-02. DOI: 10.1158/1538-7445.sabcs23-po2-06-02.
- Rozenblit M, Wiesendanger N, Shanahan K, Hodgdon C, Gershkovich P, Golshan M, Moran M, Lustberg M, Pusztai L. Abstract PO5-18-12: Can we cure de novo oligometastatic stage IV HER2+ breast cancer with multimodality therapy? (CHLOE). Cancer Research 2024, 84: po5-18-12-po5-18-12. DOI: 10.1158/1538-7445.sabcs23-po5-18-12.
- Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.
- Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay. The Oncologist 2023, 28: e973-e976. PMID: 37656608, PMCID: PMC10546821, DOI: 10.1093/oncolo/oyad249.
- Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.
- Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Sehgal R, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome. Science Advances 2023, 9: eadf4163. PMID: 37467337, PMCID: PMC10355820, DOI: 10.1126/sciadv.adf4163.
- Rozenblit M, Lin H, Can N, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner F, Pusztai L. Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®. Cancer Research 2023, 83: p2-23-14-p2-23-14. DOI: 10.1158/1538-7445.sabcs22-p2-23-14.
- Minteer C, Thrush K, Niimi P, Rozowsky J, Liu J, Frank M, McCabe T, Hofstatter E, Rozenblit M, Pusztai L, Beckman K, Gerstein M, Levine M. Abstract PR009: Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome. Cancer Research 2023, 83: pr009-pr009. DOI: 10.1158/1538-7445.agca22-pr009.
- Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.
- Rozenblit M, Blenman K, Harigopal M, Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research And Treatment 2022, 196: 221-227. PMID: 36028784, DOI: 10.1007/s10549-022-06712-2.
- Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.
- Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Institute 2022, 114: 988-995. PMID: 35417011, PMCID: PMC9275765, DOI: 10.1093/jnci/djac068.
- Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
- Rozenblit M, Lustberg MB. Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer. Annals Of Translational Medicine 2022, 0: 0-0. PMID: 35530962, PMCID: PMC9073796, DOI: 10.21037/atm-22-484.
- Rozenblit M, Hofstatter E, Liu Z, O’Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics 2022, 14: 30. PMID: 35209953, PMCID: PMC8876160, DOI: 10.1186/s13148-022-01249-z.
- Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes. Cancer Research 2022, 82: p3-07-01-p3-07-01. DOI: 10.1158/1538-7445.sabcs21-p3-07-01.
- Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.
- Rozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Cancer Research 2021, 81: ps5-08-ps5-08. DOI: 10.1158/1538-7445.sabcs20-ps5-08.
- Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.
- Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
- Rozenblit M, Pusztai L, Adelson K, Mougalian S. Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy. Cancer Research 2020, 80: p1-19-12-p1-19-12. DOI: 10.1158/1538-7445.sabcs19-p1-19-12.
- Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.
- Rozenblit M, Heguy A, Chiriboga L, Loomis C, Darvishian F, Egeblad M, Shao Y, Adams S. Identification of differentially expressed genes associated with clinical response after treatment of breast cancer skin metastases with imiquimod. Journal Of Clinical Oncology 2017, 35: e12541-e12541. DOI: 10.1200/jco.2017.35.15_suppl.e12541.
- McFarland DC, Naikan J, Rozenblit M, Mandeli J, Bleiweiss I, Tiersten A. Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years. Journal Of Oncology 2016, 2016: 4324863. PMID: 27382369, PMCID: PMC4921638, DOI: 10.1155/2016/4324863.
- Suárez-Fariñas M, Ungar B, da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, Xu H, Zheng X, Peng X, Estrada YD, Dillon SR, Krueger JG, Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. Journal Of Allergy And Clinical Immunology 2015, 135: 1218-1227. PMID: 25840722, DOI: 10.1016/j.jaci.2015.03.003.
- Rozenblit M, Guttman‐Yassky E. Contact Dermatitis. 2015, 25-35. DOI: 10.1002/9781118609125.ch3.
- da Rosa J, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Khattri S, Ungar B, Finney R, Xu H, Zheng X, Estrada YD, Peng X, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. Journal Of Allergy And Clinical Immunology 2015, 135: 712-720. PMID: 25583101, DOI: 10.1016/j.jaci.2014.11.017.
- Esaki H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Xu H, Estrada YD, Peng X, Mitsui H, Litman T, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. Journal Of Allergy And Clinical Immunology 2015, 135: 153-163. PMID: 25567045, PMCID: PMC4452382, DOI: 10.1016/j.jaci.2014.10.037.
- Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. Journal Of Allergy And Clinical Immunology 2014, 134: 955-957. PMID: 24996261, PMCID: PMC4281263, DOI: 10.1016/j.jaci.2014.05.024.
- Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, de Guzman Strong C, Gonzalez J, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal Of Allergy And Clinical Immunology 2014, 133: 1626-1634. PMID: 24786238, PMCID: PMC4122665, DOI: 10.1016/j.jaci.2014.03.003.
- Dhingra N, Shemer A, da Rosa J, Rozenblit M, Fuentes-Duculan J, Gittler JK, Finney R, Czarnowicki T, Zheng X, Xu H, Estrada YD, Cardinale I, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. Journal Of Allergy And Clinical Immunology 2014, 134: 362-372. PMID: 24768652, DOI: 10.1016/j.jaci.2014.03.009.
- Rozenblit M. 2011 Runner-Up Essay Incentives for Medical School Students to Practice Primary Care through the Lens of John Rawls. The AMA Journal Of Ethic 2012, 14: 970-976. PMID: 23351945, DOI: 10.1001/virtualmentor.2012.14.12.conl4-1212.
- Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.
- Wang G, Drake C, Rozenblit M, Zhou P, Alves S, Herrick S, Hayashi S, Warrier S, Iadecola C, Milner T. Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla. Brain Research 2006, 1094: 163-178. PMID: 16696957, DOI: 10.1016/j.brainres.2006.03.089.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. PMID: 14578094, DOI: 10.1080/jdt.14.s2.17.20.
- Spuls P, Rozenblit M, Lebwohl M. Retrospective study of the efficacy of narrowband UVB and acitretin. Journal Of Dermatological Treatment 2003, 14: 17-20. DOI: 10.1080/738528794.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2003, 14: 7-16. PMID: 14578093, DOI: 10.1080/jdt.14.s2.7.16.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/738528793.
- Maryles S, Rozenblit M, Lebwohl M. Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis. Journal Of Dermatological Treatment 2000, 14: 7-16. DOI: 10.1080/753995509.
Departments and Programs
Locations
1
1 of 2
- Long Ridge Medical Center260 Long Ridge RoadStamford, CT 06902
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830
1
1 of 2
- Long Ridge Medical Center260 Long Ridge RoadStamford, CT 06902
- Smilow Cancer Hospital at Greenwich77 Lafayette PlaceGreenwich, CT 06830